Literature DB >> 32895230

Effects of pretreatment with terazosin and valsartan on intraoperative haemodynamics in patients with phaeochromocytoma.

Qingrong Ji1, Feng Li1, Xianzhao Zhang1, Yuqiang Wang1, Cunfei Liu1, Ying Chang2.   

Abstract

OBJECTIVE: Surgery is the primary strategy for treating phaeochromocytoma (PCC), but it can lead to severe hypertension and heart failure. Although valsartan is effective in reducing high blood pressure, clinical data on the potential role of valsartan in PCC are currently limited. Therefore, the aim of this study was to investigate the effects of pretreatment with terazosin and valsartan on patients with PCC.
METHODS: In this retrospective cohort study, 50 patients who underwent laparoscopic resection of PCC were enrolled. During preoperative preparation, the patients (n=25) in the control group were treated with terazosin, while those (n=25) in the combination treatment group were treated with terazosin and valsartan. The levels of catecholamine hormones before and after surgery were determined, and the intraoperative blood pressure and the incidence of complications were compared between the two groups.
RESULTS: The results showed no significant differences in baseline patient characteristics or surgical conditions between the two groups (p>0.05). However, on the third day after surgery, the levels of catecholamine hormones in the two groups were significantly lower than those before surgery (p<0.05), while the levels in the combination treatment group were notably lower than those in the control group (p<0.05). The patients in the combination treatment group showed lower intraoperative blood pressure fluctuations and incidence of perioperative complications compared with the control group (p<0.05).
CONCLUSIONS: Terazosin combined with valsartan can effectively improve perioperative haemodynamic instability and reduce postoperative complications in the preoperative management of PCC. © European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  basic sciences; clinical pharmacy; clinical trial medication; hypertension; pharmacy design

Mesh:

Substances:

Year:  2020        PMID: 32895230      PMCID: PMC9251171          DOI: 10.1136/ejhpharm-2020-002375

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  28 in total

1.  Perioperative α-receptor blockade in phaeochromocytoma surgery: an observational case series.

Authors:  H Groeben; B J Nottebaum; P F Alesina; A Traut; H P Neumann; M K Walz
Journal:  Br J Anaesth       Date:  2017-02       Impact factor: 9.166

2.  Hemodynamic instability during surgery for pheochromocytoma: comparing the transperitoneal and retroperitoneal approach in a multicenter analysis of 341 patients.

Authors:  Wessel M C M Vorselaars; Emily L Postma; Eric Mirallie; Julien Thiery; Mattan Lustgarten; Jesse D Pasternak; Rocco Bellantone; Marco Raffaelli; Thomas Fahey; Menno R Vriens; Laurent Bresler; Laurent Brunaud; Rasa Zarnegar
Journal:  Surgery       Date:  2017-11-06       Impact factor: 3.982

3.  Preoperative Metyrosine Improves Cardiovascular Outcomes for Patients Undergoing Surgery for Pheochromocytoma and Paraganglioma.

Authors:  Heather Wachtel; Edward H Kennedy; Salman Zaheer; Edmund K Bartlett; Lauren Fishbein; Robert E Roses; Douglas L Fraker; Debbie L Cohen
Journal:  Ann Surg Oncol       Date:  2015-09-15       Impact factor: 5.344

4.  Routine genetic screening with a multi-gene panel in patients with pheochromocytomas.

Authors:  Emilia Sbardella; Treena Cranston; Andrea M Isidori; Brian Shine; Aparna Pal; Bahram Jafar-Mohammadi; Greg Sadler; Radu Mihai; Ashley B Grossman
Journal:  Endocrine       Date:  2017-05-05       Impact factor: 3.633

5.  High pre-operative urinary norepinephrine is an independent determinant of peri-operative hemodynamic instability in unilateral pheochromocytoma/paraganglioma removal.

Authors:  Rita Y K Chang; Brian Hung-Hin Lang; Kai Pun Wong; Chung-Yau Lo
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

6.  Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.

Authors:  Kimio Sugaya; Katsumi Kadekawa; Akashi Ikehara; Tomoyuki Nakayama; Munehisa Gakiya; Fumio Nashiro; Masato Goya; Tadashi Hatano; Yoshihide Ogawa
Journal:  Int J Urol       Date:  2003-11       Impact factor: 3.369

7.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

Authors:  Jacques W M Lenders; Quan-Yang Duh; Graeme Eisenhofer; Anne-Paule Gimenez-Roqueplo; Stefan K G Grebe; Mohammad Hassan Murad; Mitsuhide Naruse; Karel Pacak; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2014-06       Impact factor: 5.958

8.  Pheochromocytoma with Synchronous Ipsilateral Adrenal Cortical Adenoma.

Authors:  M Earth Hasassri; T K Pandian; Aleh A Bobr; Irina Bancos; William F Young; Melanie L Richards; David R Farley; Geoffrey B Thompson; Travis J McKenzie
Journal:  World J Surg       Date:  2017-12       Impact factor: 3.352

9.  Acute coronary syndrome: a rare case of multiple endocrine neoplasia syndromes with pheochromocytoma and medullary thyroid carcinoma.

Authors:  Alessadro Maloberti; Paolo Meani; Roberto Pirola; Marisa Varrenti; Marco Boniardi; Anna Maria De Biase; Paola Vallerio; Edgardo Bonacina; Giuseppe Mancia; Paola Loli; Cristina Giannattasio
Journal:  Cancer Biol Med       Date:  2015-09       Impact factor: 4.248

Review 10.  Current perioperative management of pheochromocytomas.

Authors:  Rashmi Ramachandran; Vimi Rewari
Journal:  Indian J Urol       Date:  2017 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.